Drawing for RAEDYONT

USPTO serial 97090507

RAEDYONT

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
DUBIN, DAVID I
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with RAEDYONT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III TEPPER & EYSTER, PLLC3724 BENSON DRRALEIGH, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations, namely, pharmaceutical preparations for use in dermatology; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
May 25, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 25, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 16, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 16, 2026EX5GSOU EXTENSION 5 GRANTED—
Mar 13, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 15, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 14, 2025EXT5SOU EXTENSION 5 FILED—
Apr 14, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 13, 2025EX4GSOU EXTENSION 4 GRANTED—
Apr 13, 2025EXT4SOU EXTENSION 4 FILED—
Apr 13, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 14, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 14, 2024EX3GSOU EXTENSION 3 GRANTED—
Oct 14, 2024EXT3SOU EXTENSION 3 FILED—
Oct 14, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 2, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 30, 2024EX2GSOU EXTENSION 2 GRANTED—
Mar 30, 2024EXT2SOU EXTENSION 2 FILED—
Mar 30, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 17, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 13, 2023EX1GSOU EXTENSION 1 GRANTED—
Oct 13, 2023EXT1SOU EXTENSION 1 FILED—
Oct 13, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 18, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 21, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 21, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 1, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 19, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 18, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 18, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 18, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 2, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2022DOCKASSIGNED TO EXAMINER—
Nov 8, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 28, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance